



PCT/GB 2003/002937



## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office

Concept House

Cardiff Road

Newport

South Wales

NP10 8QQ

RECD 08 SEP 2003


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

*R. Mahoney*  
19 August 2003

Executive Agency of the Department of Trade and Industry

BEST AVAILABLE COPY

8. JUL. 2002 9:58

Patents Form 1/77

Patents Act 1977  
(Rule 16)

HARRISON GODDARD FOO

THE PATENT OFFICE  
A

- 8 JUL 2002

The  
Patent  
Office

RECEIVED BY FAX

No 072 P. 4

08JUL02 E731347-1 D02973  
P01/7700 0.00-0215617.2

**Request for grant of a patent**

*(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)*

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP9 1RH

1. Your reference

LPB/P100591GB

2. Patent application number

*(The Patent Office will fill in this part)*

0215617.2

8 JUL 2002

3. Full name, address and postcode of the or of  
each applicant *(underline all surnames)*

University of Leeds  
LEEDS  
LS2 9JT

Patents ADP number *(if you know it)*

6243554002

If the applicant is a corporate body, give the  
country/state of its incorporation

United Kingdom

4. Title of the invention

Use of Hepatitis C Virus (HCV) p7 Protein

5. Name of your agent *(if you have one)*

Harrison Goddard Foote

"Address for service" in the United Kingdom  
to which all correspondence should be sent  
*(including the postcode)*

Belgrave Hall  
Belgrave Street  
Leeds  
LS2 8DD

Patents ADP number *(if you know it)*

14571001 7631810002

6. If you are declaring priority from one or more  
earlier patent applications, give the country  
and the date of filing of the or of each of these  
earlier applications and *(if you know it)* the or  
each application number

Country      Priority application number  
*(if you know it)*      Date of filing  
*(day / month / year)*

7. If this application is divided or otherwise  
derived from an earlier UK application,  
give the number and the filing date of  
the earlier application

Number of earlier application      Date of filing  
*(day / month / year)*

8. Is a statement of inventorship and of right  
to grant of a patent required in support of  
this request? *(Answer 'Yes' or 'No')*  
a) *any applicant named in part 3 is not an inventor, or*      yes  
b) *there is an inventor who is not named as an*  
    *applicant, or*  
c) *any named applicant is a corporate body.*  
*See note (d)*

Patents Form 1/77

0041035:08 JUL 02 10:06

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

## Continuation sheets of this form

Description 11

Claim(s) 3

Abstract 1 DML

Drawing(s) 9 (W)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 1/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

I/We request the grant of a patent on the basis of this application.

11.

Signature

Date

8 July 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr Lisa Brown

0113 233 0100

**Warning**  
 After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 32 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**  
 a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0845 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

0041035-08-JUL-02 10:06

### Use of Hepatitis C Virus (HCV) p7 Protein

The present invention relates to the use of hepatitis C virus (HCV) p7 protein, and particularly but not exclusively, to its use in rationalised drug design and as a screen 5 for antiviral therapeutic agents.

#### Background to the Invention

Hepatitis C virus (HCV) is the prototype member of the *Hepacivirinae* genus of the 10 *Flaviviridae*. The viral genome is a single coding sense RNA of around 9.5 Kilobases and encodes a single polyprotein of around 3000 amino acids translated in a cap-independent manner from an Internal Ribosome Entry Site (IRES). The polyprotein contains the viral structural proteins towards the N-terminus, and the non-structural replicative proteins in the C-terminal two thirds of the molecule. 15 Individual proteins are generated from this precursor by the action of both host and viral proteases. Replication of HCV RNA is thought to occur in the cytoplasm of the infected cell in complexes associated with cellular membranes derived from the Endoplasmic Reticulum (ER), leading to the generation of new viral progeny which are released through the secretory pathway.

20

The HCV viral polypeptide comprises 10 viral proteins in the order of:

NH<sub>2</sub>-Core-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH

Located at the junction between the viral structural and non-structural genes, the p7 25 protein of HCV is a 63 amino acid protein of a highly hydrophobic nature (accession number AF054247 (HCVJ4)). Sequence analysis suggests that p7 forms an integral membrane protein with two alpha-helical *trans*-membrane domains of an amphipathic nature separated by a short stretch of charged residues. p7 has been shown to localise to the ER and plasma membrane and is predicted to have its' 30 termini present in the ER lumen and the charged region on the cytosolic side from

topological studies. However, the function of HCV p7 in the virus life cycle is not known.

Hepatitis C virus (HCV) infection has emerged as the major cause of non-A, non-B 5 viral hepatitis (NANBH) in the world. Current estimates from the World Health Organisation predict that over 3 % of the world population are currently infected with the virus, making it a major public health issue in many countries. Exposure to HCV via contact with infected blood leads in most cases to a chronic persistent infection of the liver. Furthermore, this process is often asymptomatic thereby delaying clinical 10 intervention until late stage disease manifests in the form of liver cirrhosis, often leading to end stage liver failure or hepatocellular carcinoma; a rapidly progressive cancer with a poor prognosis. Current treatment of HCV disease comprises type 1 Interferon often in combination with Ribavirin, there being no vaccine currently 15 available. However, this treatment is often ineffective against the HCV genotypes common in the USA and Western Europe, and therefore there is a need for new and effective anti-viral agents/therapies.

#### Statement of the Invention

20 The present invention resides in the surprising observation that HCVp7 forms ion channels thus making it a suitable target for rationalised drug design of anti-viral compounds.

25 As used herein the word "comprises" is not exclusive, i.e. it indicates that the subject of the verb need not consist only of its object but may include the object of the verb and one or more additional elements. Cognate expressions are to be construed accordingly.

30 According to a first aspect of the invention there is provided use of HCVp7, a variant, functionally effective fragment or a mutation thereof in screening candidate compounds that inhibit or increase ion channel activity.

Reference herein to an HCVp7 variant, functionally effective fragment or a mutation thereof is intended to include any part of the sequence identified as accession number AF054247 (HCVJ4) or its expression products which has ion channel activity.

5 Preferably, HCVp7 is coupled to a poly(amino acid) sequence.

Coupling may be for example by covalent bonding, homo or heterofunctional linking or through chemical cross-linkage or by a natural peptide.

10 Preferably, the poly(amino acid) sequence comprising basic natural or unnatural amino acids such as ARG, LYS or HIS.

Preferably, the linker is a poly HIS comprising at least 2 and up to 50 residues.

15 Preferably, the poly HIS comprises at least 2 and up to 15, or at least 2 and up to 10 or more preferably still at least 2 and up to 6 and preferably at least 4 residues.

Preferably, the HCVp7 is incorporated into a membrane for example and without limitation a black lipid membrane.

20 In another embodiment of the invention nucleic acid encoding the HCVp7 protein, variant, functionally effective fragment or a mutation thereof is incorporated into or comprised in a viral system.

25 Reference herein to viral system is intended to include, examples such as and without limitation a herpes virus, adenovirus or pox virus vector.

According to a yet further aspect of the invention there is provided a method of screening a compound, preferably from a compound library for compounds, that  
30 inhibit or enhance ion channel activity comprising the steps of:

5

- (i) contacting a membrane comprising an HCVp7 protein or a viral system including a nucleic acid encoding an HCVp7 protein with a candidate compound; and
- (ii) measuring ion channel activity across said membrane or in viral system.

According to a yet further aspect of the invention there is provided a method of screening a compound or a compound library for efficacy of inhibition or enhanced ion channel activity comprising the steps of:

10

- (i) contacting a membrane comprising a HCVp7 protein with a candidate compound or a viral system including a nucleic acid encoding an HCVp7 protein with a candidate compound; and
- (ii) comparing the activity of said candidate compound with a standard.

15 The standard may be a known inhibitor or enhancer of ion channel activity, for example amantadine.

It will be appreciated that the methods of the present invention advantageously allow for high-throughput screening of large drug libraries for compounds that inhibit or 20 increase ion channel activity or compounds with improved efficacy over prior art compounds.

Preferably, the methods of the invention further include any one or more of the preferred features hereinbefore disclosed.

25 According to a yet further aspect of the invention there is provided use of HCVp7 in the assessment of channel formation by p7 variants and mutants thereof.

According to a yet further aspect of the invention there is provided a compound 30 identified according to the method of the invention.

According to a yet further aspect of the invention there is provided an antiviral therapeutic agent as identified by the method of the invention.

According to a yet further aspect of the invention there is provided use of a 5 therapeutic agent identified by the method of the present invention in the preparation of a medicament for the treatment of a viral infection.

According to a yet further aspect of the invention there is provided use of a 10 therapeutic agent identified by the method of the present invention in the preparation of a medicament for the treatment of hepatitis.

According to a yet further aspect of the invention there is provided use of a therapeutic agent identified by the method of the present invention in the preparation 15 of a medicament for the treatment of hepatitis C virus (HCV) infection.

According to a yet further aspect of the invention there is provided use of an antibody 20 directed against HCVp7 as an inhibitor of channel ion activity, pharmaceutical preparations thereof and use in the manufacture of a medicament for the treatment of hepatitis C virus (HCV) infection.

The invention will now be described by way of example only with reference to the 25 following Figures wherein:

Figure 1 illustrates p7 hexamerisation in membranes of HepG2 cells;

Figure 2 shows transmission electron microscope images of GSTp7 in liposomes;

Figure 3 illustrates computer modelling of p7 hexamerisation;

Figure 4 a schematic representation of a black lipid membrane (BLM);

Figure 5 shows GSTp7 voltage-gated ion channel activity in BLMs;

Figure 6 shows GSTHISp7 stabilisation;

5 Figure 7 shows GSTHISp7 calcium ion channel activity;

Figure 8 shows HISp7 calcium ion channel activity and ;

Figure 9 shows amantadine inhibits HISp7 ion channel formation.

10 **Detailed Description of the Invention**

Many animal viruses encode proteins of low molecular weight, which are hydrophobic and form oligomers. When these proteins are individually expressed in bacteria or in animal cells, they induce profound modifications in cellular permeability. These proteins therefore, have been collectively termed as "Viroporins". Amongst the viral proteins that enhance membrane permeability are poliovirus 2B, 2BC and 3A, the togavirus 6K polypeptide, influenza M2 and Vpu from HIV-1. These Viroporins are all small integral membrane proteins that oligomerise to form ion channels in cellular and often viral membranes. They usually function so as to modulate cation exchange to facilitate egress of virus particles from cells or changes to the interior of virus particles. Perhaps the most famous of these proteins is the M2 protein of Influenza A virus which is the target of the first anti-viral drug; Amantadine. We provide evidence that p7 is a Viroporin and that it too will oligomerise in membranes to form ion channels in a similar fashion as M2 thus making HCVp7 a suitable target for anti-viral compounds.

## Materials and Methods

### *BLM Experimental Procedures*

#### Solutions / Chamber Preparation

- 5 All buffer solutions were prepared by dissolving the relevant amounts of KCl, CaCl<sub>2</sub> (Both Aldrich 99+%) and PBS in Millipore water ( $\geq 18\text{M}\Omega$ ) to give the following concentrations. 0.1M, 0.2M, 0.5M, 1M and 4M. A commercially available BLM chamber was pre-cleaned by immersion in DECON/Millipore water ( $\geq 18\text{M}\Omega$ ) for 24hrs prior to all experiments. To remove all traces of detergent the chamber was
- 10 flushed with running water for at least five hours. Immediately before use the chamber was washed extensively with Millipore water ( $\geq 18\text{M}\Omega$ ) and dried in N<sub>2</sub>. Silver chloride electrodes were prepared using electrochemical deposition of chloride onto silver wire (d=1mm) from a concentrated KCl solution. Agar bridges were prepared by cleaning glass pipettes in Methanol (HPLC grade) then storing in a
- 15 drying oven. The pipettes were moulded into the correct shape using glass blowing techniques. A 4M buffer solution containing 2% bacterial agar was pipetted and the Agar bridges thus formed were stored in 4M buffer solution until required.

#### *Lipid Preparation*

- 20 A number of lipid compositions were investigated using the following methodology. A 30 $\mu\text{l}$  aliquot of phosphatidylethanolamine (25mg ml<sup>-1</sup> - Lipid Products) was added to 38 $\mu\text{l}$  of phosphatidylserine (25mg ml<sup>-1</sup> - Lipid Products). The solvent was removed with N<sub>2</sub> and the lipids were dried under vacuum for 3hours. After drying the lipids were redissolved in 30 $\mu\text{l}$  decane (Aldrich 99.5+%), vortexing as required, then 25 stored on ice prior to use.

#### *Lipid Bilayer Formation/Recording*

The two Ag/AgCl electrodes were placed in a Faraday cage to minimise noise during current recordings and connected to a computer via an AXON patchclamp filtered at 30 50Hz, an ADC interface and a DAT recorder. AXON *patchclamp* software was utilised to record and analyse the traces. A sample of the lipid in decane solution was

brushed around the chamber cup pore (200 $\mu$ m) to act as a "glue" and aid stable bilayer formation. The chambers were filled with the required buffer solution and the current and capacitance monitored to ensure that the cup pore was unblocked. A sample of the lipid solution was brushed across the cup pore until a stable 5 capacitance was recorded. The lipid was then allowed to thin and stabilise over a 15min period. Only membranes that gave zero current and specific capacitances of 0.3-1 $\mu$ F cm $^{-2}$  were used further for protein studies. The *cis* chamber was clamped and the *trans* chamber applied voltage was varied between +/-280mV to monitor the stability of the bilayer and to determine the presence of possible contaminants.

10

*Protein / Amantadine Studies*

Varying amounts (15-100 $\mu$ l) of the proteins under study (GST, GSTp7, GSTHisP7 and hisp7 in methanol or PBS- see detailed description of the invention) were injected into the *trans* compartment of the BLM chamber. After 10minutes the 15 applied voltage was varied between +/- 280mV and the resultant current signals recorded as a function of time.

To monitor the effect of amantadine (Aldrich) on the formation of ion channels, 40 $\mu$ l of amantadine (20 $\mu$ M in methanol) was added to both *cis* and *trans* compartments. 20 The current traces showing blocking of ion channels were recorded within 30secs after amantadine injection.

*Detailed protocol for cloning / expression / purification of GSTp7, GSTHisP7, and HISp7.*

25 Generation of plasmid constructs. The p7 sequence of hepatitis C virus 1B was amplified via PCR using the J4 isolate infectious clone pCVJ46LS as a template (Virology. 1998 Apr 25;244(1):161-72). PCR was carried out using a proof-reading thermostable polymerase; Vent polymerase (New England Biolabs) according to manufacturers instructions. The p7 cassette was generated using primers; newp7Fwd 30 5' - ATATATGAATTGCGGCCATGGCCTAGAGAACTTGGTG - 3' (SEQ ID NO:1) and newp7Rev 5' - ATATATACTGCAGGCGGCCGCGCGTAAGCTCG

TGGTGGTAACG - 3' (SEQ ID NO:2) . The HISp7 cassette was generated using primers; newp7Rev (above), and HISp7Fwd 5' - ATATATGAATTGGCGGCCAT GCATCATCATCATCATGCCTTAGA GAAC TTG - 3' (SEQ ID NO:3). PCR

amplified DNA was extracted with phenol/chloroform (25:1) pH 8.0, ethanol

5 precipitated, and digested with *Eco RI* and *Not I* restriction endonucleases (New England Biolabs) at 37 °C for 3 hours. Resulting sticky-ended DNAs were purified by agarose gel electrophoresis followed by phenol extraction and ligated to the

Glutathione-S-Transferase expression vector, pGEX4T1 (Amersham Pharmacia Biotech, Genbank accession number U13853) which had been digested and purified

10 in the same manner, using a rapid DNA ligation kit (Roche Diagnostics). Ligations were transformed into *E. coli* DH5α and resulting clones were confirmed by restriction digest to release the cloned fragment and by double stranded DNA sequencing (Lark Technologies, UK). Plasmids were named pGEXp7 and pGEXHISp7.

15

Expression and purification of GSTp7. A single colony from a fresh transformation of pGEXp7 was used to inoculate a 5 ml overnight culture (LB +100 µg / ml Ampicillin) grown at 30 °C. This was then used to seed a 400 ml culture which was grown at 30 °C to an OD<sub>600</sub> of 1.0. At this point, IPTG (Isopropyl β-D-

20 thiogalactopyranoside) was added to a final concentration of 0.1 mM in order to induce expression from the T<sub>aq</sub> promoter, and the cultures grown for a further 2 hours. Cells were pelleted at 6000 rpm in a Sorvall SLA-3000 rotor for 10 min at 4 °C. The resulting pellet was resuspended in 10 ml PBS containing 1 mM DTT (Dithiothreitol) and protease inhibitor cocktail (Roche Diagnostics). 0.5 ml of

25 lysozyme (10 mg / ml) was then added and the mixture incubated at room temperature for 5 min to clear. Large cellular debris was disrupted by sonication, followed by the addition of 1 ml PBS/DTT/10 % Triton X-100 and centrifugated (Sorvall SLA-1500 rotor) at 10000 rpm for 10 min to pellet debris. 1 ml of a 1:1 suspension of glutathione-sepharose beads was then added to the supernatant and the

30 mixture rotated at 4 °C for 1 h. Beads were then washed three times in PBS/DTT/protease inhibitor, and finally resuspended in PBS/DTT at a 1:1 ratio v/v.

Beads were loaded onto a gravity column (Clontech) and washed three times with 50 mM Tris-Cl, pH 8.0 to equilibrate. Fusion proteins were then eluted by the addition of 3 x 0.5 ml Tris-Cl, pH 8.0 containing 20 mM reduced Glutathione (SIGMA). The second and third elutions were pooled and dialysed using a Slide-a-lyzer cassette (Pierce Endogen) in PBS or MeOH. Purity and concentration of the protein was then determined by SDS-PAGE and BCA.

Expression and purification of GSTHISp7. GSTHISp7 was expressed and purified in the same way as GSTp7, except that instead of a starter culture, the 400 ml culture 10 was inoculated with a single colony and grown for 12 h at 30 °C before induction with 0.1 mM final concentration IPTG, followed by growth overnight at the same temperature.

Generation of HISp7 from GSTHISp7 by thrombin cleavage. Pre-dialysis, 15 GSTHISp7 was cleaved at the thrombin cleavage site present in the pGEX4T1 polylinker by the addition of 10 units / mg fusion protein thrombin (SIGMA). Incubation was carried out overnight at room temperature and the cleaved HISp7 separated by GS-trap™ (Amersham Pharmacia Biotech) chromatography followed by 20 collecting the flow-through after passing through a 10 000 MWt filter ( Microsep, Pall life sciences). Purity and concentration were then determined by mass spectrometry, SDS-PAGE and BCA.

#### EXAMPLE 1

As previously discussed, Viroporins are all small integral membrane proteins that 25 oligomerise to form ion channels in cellular and often viral membranes. They usually function so as to modulate cation exchange and to facilitate egress of virus particles from cells or changes to the interior of virus particles.

With reference to Figures 1 and 2 it has been shown that HCVp7 forms hexamers 30 both *in vitro* in HePG2 cells and *in vivo* in liposomes. Figure 3 illustrates the computer modelling of HCVp7 hexamerisation. These observations coupled with the

hydrophobic nature at the amino acid level suggest that HCVp7 is indeed a member of the Viroporin family. Figure 4 provides a schematic representation of HCVp7 incorporated in a BLM.

**5 EXAMPLE 2**

With reference to Figure 5, we have been able to demonstrate that a GSTp7 fusion protein has voltage-gated ion channel activity in BLM. Moreover, stability of the fusion protein increases by the incorporation of a 6-HIS linker as seen in Figure 6. In addition, we have been able to demonstrate that the inclusion of a 6-HIS linker 10 increases ion channel activity in the presence of both  $K^+$  and  $Ca^{2+}$  electrolytes as seen in Figure 7. The effect being more pronounced in the presence of the  $Ca^{2+}$  electrolyte.

**EXAMPLE 3**

15 We have found that removal of the GST part of the fusion protein, so that p7 is associated only with the 6-HIS linker, resulted in an unexpected 5 fold increase in ion channel activity in the presence of both  $K^+$  and  $Ca^{2+}$  electrolytes (Figure 8). The ion channel activity still being more pronounced in the presence of the  $Ca^{2+}$  electrolyte. These results are surprising since p7, which has two  $\alpha$  helices, is lipid soluble and 20 was fused to GST in order to make the molecule more soluble. Accordingly these results suggest that HISp7 acts as a voltage-gated calcium channel BLM in the absence of a fusion protein and that it represents a novel target for screening compounds that inhibit ion channel activity.

**25 EXAMPLE 4**

Our studies have demonstrated that amantadine inhibits ion channel formation by HISp7 (Figure 9) in the micromolar range. This confirms the potential use of HISp7 as a target for screening inhibition of channel activity and may lead to the discovery of alternative anti-viral therapies.

30

P100591gb.9-07-02

## Claims

1. Use of HCVp7, a variant, functionally effective fragment or a mutation thereof in screening candidate compounds that inhibit or increase ion channel activity.
2. Use according to claim 1 wherein HCVp7 is coupled to a poly(amino acid) sequence.
- 10 3. Use according to claim 2 wherein the poly(amino acid) sequence linker comprises a basic natural amino acid selected from the group comprising ARG, LYS or HIS.
4. Use according to either claim 2 or claim 3 wherein the poly(amino acid) sequence is a polyHIS sequence.
- 15 5. Use according to claim 4 wherein the polyHIS sequence comprises at least 2 and up to 50 residues.
- 20 6. Use according to claim 5 wherein the polyHIS sequence comprises at least 2 and up to 10 residues
7. Use according to any preceding claim wherein HCVp7 is incorporated into or comprised in a membrane.
- 25 8. Use according to claim 7 wherein the membrane is a black lipid membrane.
9. Use according to any one of claims 1 to 6 wherein a nucleic acid encoding the HCVp7 protein, variant, functionally effective fragment or a mutation thereof is incorporated into or comprised in a viral system.
- 30

10. A method of screening for compounds that inhibit or enhance ion channel activity comprising the steps of:

- (i) contacting a membrane comprising a HCVp7 protein or a viral system including a nucleic acid encoding an HCVp7 protein with a candidate compound; and
- 5 (ii) measuring ion channel activity across said membrane or in viral system.

11. A method of screening a compound for efficacy of inhibition or enhanced ion 10 channel activity comprising the steps of:

- (i) contacting a membrane comprising a HCVp7 protein or a viral system including a nucleic acid encoding an HCVp7 protein with a candidate compound; and
- 15 (ii) comparing the activity of said candidate compound with a standard.

12. A method according to either claim 10 or 11 further including any one or more of the features of claims 2 to 9.

13. Use of HCVp7 in the assessment of ion channel formation by p7 variants 20 and/or mutants thereof.

14. Use according to claim 13 further including any one or more of the features of claims 2 to 9.

25 15. A compound identified according to the method of any one of claims 10 to 12.

16. An antiviral therapeutic agent as identified by the method any one of claims 10 to 12.

30

17. Use of a therapeutic agent identified by the method any one of claims 10 to 12 in the preparation of a medicament for the treatment of a viral infection.

18. Use of a therapeutic agent identified by the method any one of claims 10 to 12 in the preparation of a medicament for the treatment of hepatitis.

19. Use of a therapeutic agent identified by the method of any one of claims 10 to 12 in the preparation of a medicament for the treatment of hepatitis C virus (HCV) infection.

10


20. Use of an antibody directed against HCVp7 as an inhibitor of channel ion activity, pharmaceutical preparations thereof and use therefor in the manufacture of a medicament for the treatment of hepatitis C virus (HCV) infection.

**Abstract**


The present invention relates to the use of hepatitis C virus (HCV) p7 protein, and particularly but not exclusively, to its use in rationalised drug design and as a screen for antiviral therapeutic agents.

# p7 hexamers in membranes of HepG2 cells



Figure 1.




# TEM of GSTp7 in liposomes



# Computer modelling of p7 hexamerisation



# Black Lipid Membranes (BLM)



# GSTp7 displays voltage-gated ion channel activity in Black Lipid Membranes (BLM)

No protein

0.5pA | -250mV  
2500ms

+ GST


0.5pA | -250mV  
1800ms

+ GSTp7

1pA | -250mV  
1000ms

6/9

# Stabilisation of GST fusions by introduction of 6-HIS linker; GSTHISp7




TEM of GSTTHISp7


- Unilamellar vesicles
- Biotinylated  $\alpha$ -GST m'ab
- 10 nm streptavidin-Au

# GSTTHISp7 shows calcium channel activity in BLM


## K<sup>+</sup> Electrolyte



## Ca<sup>2+</sup> Electrolyte



+GSTTHISp7




# HISp7 forms $\text{Ca}^{2+}$ channels in BLM with extremely high efficiency


No protein

100ms  
0.8pA  
100mV  
+/- 200mV NO Protein

+ HISp7  
( $\text{K}^+$  electrolyte)




+ HISp7  
( $\text{Ca}^{2+}$  electrolyte)



Amantadine inhibits ion channel formation by

HISp7



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record.**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**